AstraZeneca Upgrades Shanghai R&D Platform to Global Hub, Focusing on AI, Big Data, and Innovative Drug Development

AstraZeneca Announces Further Upgrade of Strategic Cooperation with Shanghai Municipal Government, Upgrading Its Existing Shanghai R&D Platform into a Global R&D Center and Establishing an AI Innovation Center

Future collaborations will focus on new drug development, artificial intelligence (AI) in healthcare, and big data integration services. Lei Wang, Executive Vice President of AstraZeneca, President of International Business and China, told Jiemian News that the company aims to shift the role of China in new drug clinical trials from participating in global studies to leading global clinical development through China-based trials.